- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT03580226
Glycated Hemoglobin Targets and Glycemic Control in Indonesian Diabetic Patients
Glycated Hemoglobin Targets and Glycemic Control: Link With Lipid, Uric Acid and Kidney Profile in Indonesian Diabetic Patients
Aperçu de l'étude
Description détaillée
Adult patients (≥ 18 years of age) with type 2 diabetes which are diagnosed under ICD-10 coding of E-11 were included in this study. The inclusion criteria are patients with primary diagnosis of E11and have visited the clinic at least twice with a complete record of glucose, uric acid, lipid and kidney profile. Participants were grouped into 2 groups - good and poor glycemic control based on their glycated hemoglobin (HbA1c) levels. Good glycemic control is defined according to the American Diabetes Association and the Indonesian Association of Endocrinologists (PERKENI) cut off of HbA1c < 7.0.
Data such as age, sex, ethnic, education, BMI, glucose, uric acid, lipid, and kidney profile as well as comorbidities and type of drug used were collected from the patients' medical records. Comorbid conditions were defined as either concomitant hypertension, dyslipidemia, chronic kidney disease, hyperuricemia, or combinations of them as diagnosed in the medical records. Diabetic complications of interest include macrovascular (heart disease, stroke), microvascular (nephropathy, retinopathy, neuropathy) and a combination of both as well as infection (urinary tract infection, pneumonia). These complications were also based on the medical records. Management modalities included were lifestyle modification, use of oral antidiabetic medications or insulin, or both.
Type d'étude
Inscription (Réel)
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Clinical diagnosis of Type 2 Diabetes
- Must have visited the clinic at least twice, one before and one post-therapy
Exclusion Criteria:
- Type 1 Diabetes, Gestational Diabetes and other secondary diabetes types
- Unavailability of HbA1c results - pre and post-therapy
- Incomplete records of glucose, uric acid, lipid and kidney profile, comorbidities and management.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: Autre
- Perspectives temporelles: Rétrospective
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
---|---|
Good glycemic control
Good glycemic control is defined according to the American Diabetes Association and the Indonesian Association of Endocrinologists (PERKENI) cut off of HbA1c < 7.0.
|
Aucune intervention
|
Poor glycemic control
Poor glycemic control is defined according to the American Diabetes Association and the Indonesian Association of Endocrinologists (PERKENI) cut off of HbA1c >= 7.0.
|
Aucune intervention
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Lipid Profile
Délai: Through study completion, an average of 1 year
|
Low-density lipoprotein (LDL), high-density lipoprotein (HDL), total cholesterol and triglyceride levels.
|
Through study completion, an average of 1 year
|
Kidney Profile
Délai: Through study completion, an average of 1 year
|
Urea, Creatinine levels and Proteinuria
|
Through study completion, an average of 1 year
|
Uric Acid
Délai: Through study completion, an average of 1 year
|
Uric Acid Levels
|
Through study completion, an average of 1 year
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Comorbidities
Délai: Through study completion, an average of 1 year
|
Comorbid conditions were defined as either concomitant hypertension, dyslipidemia, chronic kidney disease, hyperuricemia, or combinations of them.
Diabetic complications of interest include macrovascular (heart disease, stroke), microvascular (nephropathy, retinopathy, neuropathy) and a combination of both as well as infection (urinary tract infection, pneumonia).
|
Through study completion, an average of 1 year
|
Management
Délai: Through study completion, an average of 1 year
|
Management modalities included were lifestyle modification, use of oral antidiabetic medications or insulin, or both.
|
Through study completion, an average of 1 year
|
Collaborateurs et enquêteurs
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- APS001
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Aucune intervention
-
Otsuka Pharmaceutical Factory, Inc.CelerionComplété
-
University of MinnesotaComplété
-
Assistance Publique - Hôpitaux de ParisComplété
-
Milton S. Hershey Medical CenterPas encore de recrutementMaladies du foie | NASH - Stéatohépatite non alcoolique | NASH
-
University of CologneComplétéAccident vasculaire cérébral | ApraxieAllemagne
-
Northwestern UniversityComplétéLa dépression | AnxiétéÉtats-Unis
-
H2O Health and Agriculture LLCInconnuePneumonie | DiarrhéeGuatemala
-
Eunah Cho, MDComplétéRécupération postopératoireCorée, République de
-
University of California, Los AngelesInconnue
-
Johns Hopkins UniversityAstraZenecaInscription sur invitationCancer du poumon non à petites cellules (NSCLC)États-Unis